Sideroflexin1 as a novel tumor marker independently predicts survival in lung adenocarcinoma

BACKGROUND: Targeted therapy for lung cancers is based on prognostic genes and needs more investigation. No study has yet evaluated the effects of Sideroflexin1 (SFXN1) on lung cancer. METHODS: Data were analyzed from large patient cohorts in the Cancer Genome Atlas (TCGA) and the Gene Expression Om...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qijiu, Wang, Rong, Zhang, Jianyong, Zhou, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798550/
https://www.ncbi.nlm.nih.gov/pubmed/35116859
http://dx.doi.org/10.21037/tcr.2019.06.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798550/
https://www.ncbi.nlm.nih.gov/pubmed/35116859
http://dx.doi.org/10.21037/tcr.2019.06.34

Ejemplares similares